A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction

Exclusion Criteria

• •Hypersensitivity to sulfonamides or acetazolamide-
• •Patients with ongoing medication with other sulphonamides or patients any specific antihypertensive treatment.
• •History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity.
• •Subjects with a seizure disorder
• •Patients with clinically verified central sleep apnea
• •Clinically significant renal (serum creatinine \>2.0 mg/dL or \>130 micromol/L), neurological, metabolic (e.g. Type 1 or 2 diabetes), haematological or hepatic disease (ASAT or ALAT \>2 times the upper limit of normal).
• •Subjects with an occupational risk potentially exaggerated by daytime sleepiness such as handling complex machinery or professional driving
• •Unstable angina pectoris, unstable hypertension (or poorly controlled diabetes (HbA1C \< 52 mmoles/mol, or fasting plasma glucose \>7 mmoles/l).
• •Clinically significant congestive heart failure.
• •Myocardial infarction or coronary vessel intervention within the previous 6 months period.
• •Subjects with uncontrolled hypertension (defined as a diastolic blood pressure ≥110 mmHg and/or a systolic blood pressure ≥180 mmHg with or without medication).
• •Previously diagnosed or treated clinically significant cardiac arrhythmia
• •Clinically significant chronic pulmonary or gastrointestinal disease.
• •Clinical history of depression as judged by the investigator or other previous or present clinically significant psychiatric disease
• •Suspected or confirmed poor compliance
• •Alcohol or drug abuse during the last year.
• •Subjects with any other significant condition that, in the opinion of the investigator, could interfere with participation in the study.
• •Severe nocturnal hypoxia defined as more than 10 episodes with an oxygen desaturation exceeding 50% or signs of lacking resaturation between desaturations on previous recordings according to investigators judgment
• •Participation in another clinical study during the last 6 months.
• •Inability to understand and complete the questionnaires.